Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

Abstract: The present invention provides a process for preparing remifentanil hydrochloride having an improved impurity profile.

Abstract: The present invention provides a process for the preparation of a compound of formula (2): the process comprising reacting a compound of formula (1), a base and an alkylating agent R4—X in a nitrile-containing polar aprotic solvent to form the compound of formula (2), wherein the process is carried out at a temperature greater than 60° C.; and wherein R1, R2, R3, R4, and X are as defined in the specification.

Abstract: This disclosure relates to a method of inspecting a physical asset(s) using a mobile computing device is disclosed. Data regarding the asset the location of the asset is collected on the mobile device by a user and may include dual camera photographs, audio or picture in picture video recordings, text or other types of data. The data is automatically date and time stamped and the GPS coordinate of each asset that is located from the device with the RFID adhered to the asset. The data is transmitted to a server and saved in a manner such that it may not be modified.

Abstract: A cooling device comprises a thermally conductive material preferably having a large surface area, such as a plurality of fins. The cooling device clamps or slides onto an energy-introducing cannula and can exchange heat with the surrounding air, or with a coolant enclosed in a camber or shroud around the cooling device. The coolant can be circulated via a pump connected to the shroud. The device and/or shroud can be stabilized and positioned by a positioning cone or spacer. The cooling device and method reduces, minimizes or eliminates thermal effects at critical points along the cannula, while enabling the distal end of the cannula, at which treatment is occurring, to reach a temperature sufficient to kill tumor cells.

Abstract: The underlying genetic defect of Huntington disease (HD) has been mapped to chromosomal band 4.sub.p 16.3. Refined localization using recombinant HD chromosome analysis and allelic association analyses have identified two distinct candidate regions. Using a cDNA hybrid selection procedure, .alpha.-adducin has been mapped to the proximal 2.2 Mb 4D gene candidate region within 20 kb of D4S95. Several clones have been mapped within the minimal region containing the HD gene. The clones GT 70 and GT 149 are particularly useful in detecting changes in this portion of the gene of HD patients.